Asif Ali, MD
Cardiovascular Disease · Houston, TXNPI 1881621993
Payments from drug & device makers
Across 999 payments — averaging $410.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$143K
- Lilly USA, LLC$118K
- Preventric Diagnostics, Inc.$78K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$51K
- Abbott$5K
- Novartis$3K
- plus $13K from 54 others
Across 1 payment — averaging $119.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$119
What the payments were for
- Consulting fees$81,83320%
- Speaking & faculty fees$286,70870%
- Travel & lodging$15,4854%
- Food & beverage$26,3526%
- Education$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$249,348
- BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM$78,083
- LifeVest$49,168
- Confirm Rx$1,627
- LEQVIO$502
- Carnation Ambulatory Monitor$335
- OPTIMIZER$304
- Repatha$274
- XARELTO$266
- ELIQUIS$265
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$263
- Resolute$261
- Cleerly Labs$261
- Quartet CRT Lead$254
- COROFLOW$232
- QUARTET$231
- Watchman$218
- Ovation$182
- AFX$182
- Merlin Connectivity and Remote$157
How this compares
$410,524 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $125,291 |
| EntrestoSacubitril/Valsartan | 71 | $59,064 |
| JardianceEmpagliflozin | 63 | $54,045 |
| XareltoRivaroxaban | 50 | $52,700 |
| EdarbiAzilsartan Medoxomil | 55 | $28,060 |
| Repatha SureclickEvolocumab | 20 | $16,721 |
| CorlanorIvabradine Hcl | 15 | $11,980 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 23 | $9,720 |
| Olmesartan Medoxomil | 309 | $3,741 |
| Droxidopa | 16 | $3,693 |
| LivaloPitavastatin Calcium | 11 | $3,413 |
| Metoprolol Succinate | 254 | $2,836 |
| Ezetimibe | 106 | $2,456 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 19 | $2,303 |
| Amlodipine Besylate | 294 | $1,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $537 | $125,291119 claims |
| NovartisEntresto | $2,551 | $59,06471 claims |
| Boehringer IngelheimJardiance | $143,053 | $54,04563 claims |
| Johnson & JohnsonXarelto | $872 | $52,70050 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $417 | $37,78078 claims |
| AmgenCorlanor | $822 | $11,98015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.